Pharmaceutical News

RSS

Janssen ranked among 100 Best Companies to Work for in the UK

Janssen, a pharmaceutical company of Johnson & Johnson, is celebrating being ranked number 30 out of 100 Best Companies to Work for and being awarded the highest three star Best Companies Accreditation in research conducted by Best Companies in the UK and published by the Sunday Times.

1 Mar 2016

New combination treatment shows promise for treating acute myeloid leukaemia

Walter and Eliza Hall Institute researchers have discovered that the treatment of the most deadly form of blood cancer may be improved by combining two recently developed drugs.

1 Mar 2016

New report explores strategies involved in developing and commercializing FDC products

Fixed dose combination (FDC) products, which have been around for many years, can have both clinical and commercial advantages. Successful FDC products require thoughtful planning, beginning early in the product development and lifecycle management processes.

27 Feb 2016

PCSK9-inhibitor drugs: A game-changer for individuals with extremely high cholesterol levels

A 59-year-old heart patient with dangerously high levels of cholesterol that could not be adequately reduced by statin drugs now has near-normal cholesterol levels, thanks to a new class of drugs that grew out of work done by UT Southwestern Medical Center researchers.

27 Feb 2016

Changes in use of anemia drugs affects risk of death or cardiovascular events in dialysis patients

A new study examines whether recent changes in the use of anemia drugs for patients on dialysis have contributed to changes in rates of death or cardiovascular events. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology, indicate that these risks appear to be decreasing for patients on dialysis as well as for older adults (Medicare beneficiaries) who are not on dialysis.

27 Feb 2016

Research unveils standard front-line treatment for advanced ovarian cancer

Research led by a Dignity Health St. Joseph's Hospital and Medical Center physician on ovarian cancer was published in the Feb. 24, 2016 issue of New England Journal of Medicine. The research was directed by Bradley J. Monk, M.D. and researchers at 12 other medical facilities around the nation.

27 Feb 2016

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

27 Feb 2016

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

27 Feb 2016

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

27 Feb 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration of Desoximetasone Ointment USP 0.25%, the generic equivalent of Topicort Ointment, 0.25%, of Taro Pharmaceuticals U.S.A., Inc.

26 Feb 2016

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy.

26 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

Nearly two-thirds of herbal medicines have potential health risks to cancer patients

Nearly two-thirds of the herbal medicines used by cancer patients in the Middle East have potential health risks, according to a new survey led by Assistant Professor Eran Ben-Arye, of the Technion-Israel Institute of Technology.

26 Feb 2016

Researchers unravel biochemical action of antimalarial drug

Malaria is a worldwide menace. According to the Centers for Disease Control and Prevention, over 500,000 individuals died from malaria in 2013 alone. While treatments for the disease exist, cures can also take a hefty physical toll.

26 Feb 2016

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

A study published online ahead of print in the journal Medical Care shows that over a recent 10-year period, the rate of metastatic colorectal cancer patients older than age 75 receiving three or more treatments increased from 2 percent to 53 percent.

26 Feb 2016

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Niemann-Pick Type C (NPC) disease is a rare, fatal neurodegenerative disease for which there is currently no cure. NPC primarily strikes children before and during adolescence and affects one in every 150,000 children. The disease causes cholesterol and other lipids to build up in the body's cells, which results in symptoms such as delayed motor development, deterioration of memory and balance, and seizures.

26 Feb 2016

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Allergan plc, a leading global pharmaceutical company, today announced that the Company has received approval from the U.S. Food and Drug Administration to market ACZONE (dapsone) Gel, 7.5%, a new prescription topical treatment for acne in patients 12 years of age and older.

26 Feb 2016

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings.

26 Feb 2016

Immune-suppressing drug can improve cognitive ability of patients with schizophrenia

A recent study of a handful of patients supports mounting evidence that targeted suppression of inflammation packaged with standard therapy can improve the cognitive ability of patients with schizophrenia, physician-scientists report.

25 Feb 2016

Pharmaceutical News

Janssen ranked among 100 Best Companies to Work for in the UK

New combination treatment shows promise for treating acute myeloid leukaemia

New report explores strategies involved in developing and commercializing FDC products

PCSK9-inhibitor drugs: A game-changer for individuals with extremely high cholesterol levels

Changes in use of anemia drugs affects risk of death or cardiovascular events in dialysis patients

Research unveils standard front-line treatment for advanced ovarian cancer

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

New drug shows promise against Huntington's disease

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Teligent obtains FDA approval for Desoximetasone Ointment USP 0.25%

Lilly announces CHMP positive opinion for ixekizumab for treatment of adults with plaque psoriasis

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Nearly two-thirds of herbal medicines have potential health risks to cancer patients

Researchers unravel biochemical action of antimalarial drug

Study shows high cost, high side effects and little gain for chemotherapy in older mCRC patients

New Notre Dame research may lead to a therapy for Niemann-Pick Type C disease

Allergan receives FDA approval to market ACZONE (dapsone) Gel, 7.5% for acne treatment

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Immune-suppressing drug can improve cognitive ability of patients with schizophrenia

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News